tbuckley/cabot-search huggingface dataset:
Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant
Authors: Michelle Pirotte, Marianne Fillet, Laurence Seidel, Aurélie Jaspers, Fréderic Baron, Yves Beguin
Journal: American Journal of Hematology (2021)

Hematopoietic cell transplantation (HCT) brings important alterations in erythropoiesis and iron metabolism. Hepcidin, which regulates iron metabolism, increases in iron overload or inflammation and decreases with iron deficiency or activated erythropoiesis. Erythroferrone (ERFE) is the erythroid regulator of hepcidin. We investigated erythropoiesis and iron metabolism after allogeneic HCT in 70 patients randomized between erythropoietin (EPO) treatment or no EPO, by serially measuring hepcidin, ERFE, CRP (inflammation), soluble transferrin receptor (sTfR, erythropoiesis), serum iron and transferrin saturation (Tsat; iron for erythropoiesis) and ferritin (iron stores). We identified biological and clinical factors associated with serum hepcidin and ERFE levels. Serum ERFE correlated overall with sTfR and reticulocytes and inversely with hepcidin. Erythroferrone paralleled sTfR levels, dropping during conditioning and recovering with engraftment. Inversely, hepcidin peaked after conditioning and decreased during engraftment. Erythroferrone and hepcidin were not significantly different with or without EPO. Multivariate analyses showed that the major determinant of ERFE was erythropoiesis (sTfR, reticulocytes or serum Epo). Pretransplant hepcidin was associated with previous RBC transfusions and ferritin. After transplantation, the major determinants of hepcidin were iron status (ferritin at all time points and Tsat at day 56) and erythropoiesis (sTfR or reticulocytes or ERFE), while the impact of inflammation was less clear and clinical parameters had no detectable influence. Hepcidin remained significantly higher in patients with high compared to low pretransplant ferritin. After allogeneic HCT with or without EPO therapy, significant alterations of hepcidin occur between pretransplant and day 180, in correlation with iron status and inversely with erythroid ERFE.
Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association With Common Driver Mutations
Authors: Chaoqiang Deng, Qiang Zheng, Yang Zhang, Yan Jin, Xuxia Shen, Xiao Nie, Fangqiu Fu, Xiangyi Ma, Zelin Ma, Zhexu Wen, Shengping Wang, Yuan Li, Haiquan Chen
Journal: Journal of Thoracic Oncology (2021)
Coronary Artery Calcium Scoring for Adults at Borderline 10-Year ASCVD Risk
Authors: S.M. Iftekhar Uddin, Albert D. Osei, Olufunmilayo Obisesan, Omar Dzaye, Zeina Dardari, Michael D. Miedema, John A. Rumberger, Daniel S. Berman, Matthew J. Budoff, Michael J. Blaha
Journal: Journal of the American College of Cardiology (2021)
Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment
Authors: Hayley Barnes, Lauren Troy, Cathryn T. Lee, Anne Sperling, Mary Strek, Ian Glaspole
Journal: Allergy (2021)

Hypersensitivity pneumonitis is an immune-mediated interstitial lung disease caused by an aberrant response to an inhaled exposure, which results in mostly T cell-mediated inflammation, granuloma formation, and fibrosis in some cases. HP is diagnosed by exposure identification, HRCT findings of ground-glass opacities, centrilobular nodules, and mosaic attenuation, with traction bronchiectasis and honeycombing in fibrotic cases. Additional testing including serum IgG testing for the presence of antigen exposure, bronchoalveolar lavage lymphocytosis, and lung biopsy demonstrating granulomas, inflammation, and fibrosis, increases the diagnostic confidence. Treatment for HP includes avoidance of the implicated exposure, immunosuppression, and anti-fibrotic therapy in select cases. This narrative review presents the recent literature in the understanding of the immunopathological mechanisms, diagnosis, and treatment of HP.
Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy
Authors: Montserrat Fernandez‐Rivas, Andrea Vereda, Brian P. Vickery, Vibha Sharma, Caroline Nilsson, Antonella Muraro, Jonathan O'B. Hourihane, Audrey DunnGalvin, George du Toit, Katharina Blumchen, Kirsten Beyer, Alex Smith, Robert Ryan, Daniel C. Adelman, Stacie M. Jones
Journal: Allergy (2021)

Abstract Background The benefit of daily administration of Peanut ( Arachis hypogaea ) Allergen Powder‐dnfp (PTAH)—formerly AR101—has been established in clinical trials, but limited data past the first year of treatment are available. This longitudinal analysis aimed to explore the impact of continued PTAH therapeutic maintenance dosing (300 mg/day) on efficacy, safety/tolerability, and food allergy‐related quality of life. Methods We present a subset analysis of PALISADE‐ARC004 participants (aged 4–17 years) who received 300 mg PTAH daily for a total of ~1.5 (Group A, n = 110) or ~2 years (Group B, n = 32). Safety assessments included monitoring the incidence of adverse events (AEs), accidental exposures to food allergens, and adrenaline use. Efficacy was assessed by double‐blind, placebo‐controlled food challenge (DBPCFC); skin prick testing; peanut‐specific antibody assays; and Food Allergy Quality of Life Questionnaire (FAQLQ) and Food Allergy Independent Measure (FAIM) scores. Results Continued maintenance with PTAH increased participants’ ability to tolerate peanut protein: 48.1% of completers in Group A ( n = 50/104) and 80.8% in Group B ( n = 21/26) tolerated 2000 mg peanut protein at exit DBPCFC without dose‐limiting symptoms. Immune biomarkers showed a pattern consistent with treatment‐induced desensitization. Among PTAH‐continuing participants, the overall and treatment‐related exposure‐adjusted AE rate decreased throughout the intervention period in both groups. Clinically meaningful improvements in FAQLQ and FAIM scores over time suggest a potential link between increased desensitization as determined by the DBPCFC and improved quality of life. Conclusions These results demonstrate that daily PTAH treatment for peanut allergy beyond 1 year leads to an improved safety/tolerability profile and continued clinical and immunological response.
Homeostatic maintenance of the lymphatic vasculature
Authors: Simon Stritt, Katarzyna Koltowska, Taija Mäkinen
Journal: Trends in Molecular Medicine (2021)

The lymphatic vasculature is emerging as a multifaceted regulator of tissue homeostasis and regeneration. Lymphatic vessels drain fluid, macromolecules, and immune cells from peripheral tissues to lymph nodes (LNs) and the systemic circulation. Their recently uncovered functions extend beyond drainage and include direct modulation of adaptive immunity and paracrine regulation of organ growth. The developmental mechanisms controlling lymphatic vessel growth have been described with increasing precision. It is less clear how the essential functional features of lymphatic vessels are established and maintained. We discuss the mechanisms that maintain lymphatic vessel integrity in adult tissues and control vessel repair and regeneration. This knowledge is crucial for understanding the pathological vessel changes that contribute to disease, and provides an opportunity for therapy development.
Abstract 11608: Induction of Cardiomyocyte Proliferation via Transient Expression of Cell Cycle Factors as a Promising Therapy for Heart Failure
Authors: Riham Abouleisa, Qinghui Ou, Xian-liang Tang, Yan Li, Wenjian Wu, Heather Stowers, Nashwah Alhariry, Ahmed Elshaer, Rama Nassri, Asma Hagsharfi, Roberto Bolli, Tamer m Mohamed
Journal: Circulation (2019)

Rationale: Heart failure kills 1 in 10 people over the age of 65 in the USA. Recently, we identified a combination of four cell cycle regulators, cyclin-dependent kinase 1 (CDK1), CDK4, cyclin B1, ...
Surgical Repair of Unruptured Pseudoaneurysm of Sinus of Valsalva in Aortic Stenosis
Authors: Deepak Bohra
Journal: Clinical Cardiology and Cardiovascular Interventions (2021)

Isolated pseudoaneurysm of a sinus of Valsalva is an uncommon sequelae of infective endocarditis. It is very uncommon in native aortic valve stenosis as compared to aortic regurgitation. We present a case of a 46 year old gentleman with a severely stenotic aortic valve with infective endocarditis, and a pseudoaneurysm of the non coronary sinus of Valsalva. The pseudoaneurysm was repaired with a prosthetic patch and the aortic valve was replaced by a mechanical prosthesis. Transthoracic echocardiography and computed tomography aortogram are an ideal diagnostic tools in suspected cases. Surgery can be curative with excellent results.
Therapeutic inhibitory RNA in head and neck cancer via functional targeted lipid nanoparticles
Authors: Liyona Kampel, Meir Goldsmith, Srinivas Ramishetti, Nuphar Veiga, Daniel Rosenblum, Anna Gutkin, Sushmita Chatterjee, Moran Penn, Galya Lerman, Dan Peer, Nidal Muhanna
Journal: Journal of Controlled Release (2021)
Molecular imaging of inflammation crosstalk along the cardio-renal axis following acute myocardial infarction
Authors: Rudolf A. Werner, Annika Hess, Tobias Koenig, Johanna Diekmann, Thorsten Derlin, Anette Melk, James T. Thackeray, Johann Bauersachs, Frank M. Bengel
Journal: Theranostics (2021)

Rationale: Acute myocardial infarction (MI) triggers a systemic inflammatory response including crosstalk along the heart-kidney axis.We employed radionuclide-based inflammation-targeted wholebody molecular imaging to identify potential cardio-renal crosstalk after MI in a translational setup.Methods: Serial whole-body positron emission tomography (PET) with the specific CXCR4 ligand 68 Ga-Pentixafor was performed after MI in mice.Tracer retention in kidneys and heart was compared to hematopoietic organs to evaluate systemic inflammation, validated by ex vivo analysis and correlated with progressive contractile dysfunction.Additionally, 96 patients underwent 68 Ga-Pentixafor PET within the first week after MI, for systems-based image analysis and to determine prognostic value for adverse renal outcome.Results: In mice, transient myocardial CXCR4 upregulation occurred early after MI.Cardiac and renal PET signal directly correlated over the time course (r = 0.62, p < 0.0001), suggesting an inflammatory link between organs.Ex-vivo autoradiography (r = 0.9, p < 0.01) and CD68 immunostaining indicated signal localization to inflammatory cell content.Renal signal at 7d was inversely proportional to left ventricular ejection fraction at 6 weeks after MI (r = -0.79,p < 0.01).In patients, renal CXCR4 signal also correlated with signal from infarct (r = 0.25, p < 0.05) and remote myocardium (r = 0.39, p < 0.0001).Glomerular filtration rate (GFR) was available in 48/96 (50%) during follow-up.Worsening of renal function (GFR loss >5 mL/min/1.73m 2 ), occurred a mean 80.5 days after MI in 16/48 (33.3%).Kaplan-Meier analysis revealed adverse renal outcome for patients with elevated remote myocardial CXCR4 signal (p < 0.05).Multivariate Cox analysis confirmed an independent predictive value (relative to baseline GFR, LVEF, infarct size; HR, 5.27).Conclusion: Systems-based CXCR4-targeted molecular imaging identifies inflammatory crosstalk along the cardio-renal axis early after MI.
Comments on Computed Tomography for Evaluating Appendicitis
Authors: Cynthia H. McCollough, David W. Jordan, Lawrence T Dauer
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2022 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Abstract 9347: Comparison of Cardiac Stem Cells and Mesenchymal Stem Cells Transplantation on the Cardiac Electrophysiology in Rat Model of Myocardial Infarction
Authors: Tong Wang, Shaoxin Zheng, Changqing Zhou, Zhuzhi Wen, Yinlun Weng, Hui Huang, Wei Wu, Jingfeng Wang
Journal: Circulation (2011)

Introduction Whether transplanted cardiac stem cells (CSCs) and mesenchymal stem cells (MSCs) improved ventricular fibrillation threshold (VFT) similarly and whether severe malignant ventricular arrhythmia is induced in the myocardial infarction (MI) model are still unclear. We sought to compare the effects of the CSCs and MSCs transplantation on the electrophysiological characteristics and VFT. Hypothesis CSCs are superior to MSCs in modulating the electrophysiological abnormality and improving the VFT in rat model of MI. Methods MI was induced in 30 male Sprague-Dawley rats. Two weeks later, animals were randomized to receive 5×10 6 CSCs or 5×10 6 MSCs labeled with PKH26 in phosphate buffer solution (PBS) or PBS alone injection into the infarcted anterior ventricular free wall. Six weeks after the CSCs or MSCs or PBS injection, electrophysiological characteristics and VFT were measured. Labeled CSCs and MSCs were observed in 5 µm cryostat sections from each harvested heart. Results The VFTs were improved in the CSCs group compared with the MSCs group (table 1). Labeled CSCs and MSCs were identified in the infarct zone and infarct marginal zone. Labeled CSCs express Connexin-43 and α-sarcomeric actin, while Labeled MSCs express α-sarcomeric actin in vivo. Conclusions CSCs are superior to MSCs in improving the VFT in rats with MI. CSCs and MSCs express markers that suggest muscle phenotypes in vivo, but MSCs rarely express Connexin-43.
Acupuncture for Cancer Survivors
Authors: Sajeenth Vishnu K, Riccardo Williams, Ambrutha Sivakumar
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 17786: Presence of an Esophageal Temperature Probe During Pulmonary Vein Isolation: Is There an Increased Risk for Esophageal Lesion Development?
Authors: Alexander Fuernkranz, Andreas Metzner, Roland Tilz, Shibu Mathew, Erik Wissner, Andreas Rillig, Feifan Ouyang, Karl-Heinz Kuck
Journal: Circulation (2011)

Background: Luminal esophageal temperature (LET) measurement is investigated as a tool to decrease risk of esophageal lesion formation during pulmonary vein isolation using radiofrequency (RF) current. However, recent evidence from duty-cycled phased RF ablation revealed a possible contributing role of the esophageal probe to lesion formation by direct tissue heating or interaction with the ablation device. Whether the presence of a LET probe may increase lesion formation during conventional irrigated RF ablation has not yet been investigated. Methods and Results: 62 patients (65% male, age 63±11 years, LA 44±10 mm) with drug-resistant atrial fibrillation underwent circumferential pulmonary vein isolation (PVI) using irrigated RF energy and a 3D-mapping system. A maximum power of 30 Watts was applied at the left atrial posterior wall (LAPW). In 30 patients a LET probe with 5 metal electrodes (3 thermistors) was placed in the esophagus and continuously adjusted to the level of the target pulmonary vein (group 1). LET measurement was observational only and no temperature cutoff was used. In the remaining 32 patients, no LET probe was placed (group 2). All patients underwent gastro-esophagoscopy 2±1 days after the procedure. The cumulative RF energy applied to the LAPW was 21368±9449 Joules (group 1) and 18092±8143 Joules (group 2, p=0,15). Esophageal lesions were found in 12 patients (40%) of group 1 (ulcerations: 4, erythema: 8), and 11 patients (34%) of group 2 (ulcerations: 5, erythema: 4); p=0,65. Lesions healed without clinical sequelae on proton pump inhibitor therapy in all patients. Within group 1, maximum LET in patients with and without lesions was 45,7±3,7 °C and 43,8±3,9 °C, respectively (p=0,20). Conclusion: The incidence of reversible esophageal lesions after circumferential PVI using irrigated RF energy was similar whether or not a temperature probe was present in the esophagus when no temperature cutoff was used.
Salt-and-Pepper Skin Changes in Systemic Sclerosis
Authors: Matthew Colquhoun, Henry Penn
Journal: New England Journal of Medicine (2021)

A 68-year-old man presented with skin changes on his chest and back and with shortness of breath. Examination showed “salt-and-pepper” skin changes, and computed tomography revealed fibrotic changes in the lower lobes of both lungs. A diagnosis of systemic sclerosis was made.
GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study
Authors: Premal H. Thaker, William H. Bradley, Charles A. Leath, Camille Gunderson Jackson, Nicholas Borys, Khursheed Anwer, Lauren Musso, Junko Matsuzaki, Wiam Bshara, Kunle Odunsi, Ronald D. Alvarez
Journal: Clinical Cancer Research (2021)

GEN-1 (phIL-12-005/PPC), an IL12 plasmid formulated with polyethyleneglycol-polyethyleneimine cholesterol lipopolymer, has preclinical activity when combined with platinum-taxane intravenous chemotherapy and administered intraperitoneally in epithelial ovarian cancer (EOC) models. OVATION I was a multicenter, nonrandomized, open-label phase IB trial to evaluate the safety, preliminary antitumor activity, and immunologic response to GEN-1 in combination with neoadjuvant chemotherapy (NACT) carboplatin-paclitaxel in patients with advanced EOC.
P-28 Exploratory analysis of patients with gastric/GEJ adenocarcinoma with or without liver metastasis from the phase 3 RAINBOW study
Authors: T. Ogata, Y. Narita, Z. Wainberg, E. Van Cutsem, K. Yamaguchi, Y. Piao, Y. Zhao, S. Wijayawardana, P. Abada, A. Chatterjee, K. Muro
Journal: Annals of Oncology (2021)
High Oxalate Concentrations Correlate with Increased Risk for Sudden Cardiac Death in Dialysis Patients
Authors: Anja Pfau, Theresa Ermer, Steven G. Coca, Maria Clarissa Tio, Bernd Genser, Martin Reichel, Fredric O. Finkelstein, Winfried März, Christoph Wanner, Sushrut S. Waikar, Kai-Uwe Eckardt, Peter S. Aronson, Christiane Drechsler, Felix Knauf
Journal: Journal of the American Society of Nephrology (2021)

Significance Statement Oxalate is a toxic end product of metabolism that is highly elevated in patients with kidney failure requiring chronic dialysis. Basic research has demonstrated that oxalate is a potential trigger of systemic inflammation, progression of CKD, and cardiovascular complications. The authors conducted a post-hoc analysis of the randomized German Diabetes Dialysis Study of 1255 European patients with diabetes on hemodialysis. In their analysis of 1108 patients, they found those with higher serum oxalate concentrations were more likely than those with lower levels of serum oxalate to experience cardiovascular mortality, particularly sudden cardiac death. These findings suggest oxalate-lowering therapeutic strategies might have potential for decreasing cardiovascular mortality in patients with kidney disease. Background The clinical significance of accumulating toxic terminal metabolites such as oxalate in patients with kidney failure is not well understood. Methods To evaluate serum oxalate concentrations and risk of all-cause mortality and cardiovascular events in a cohort of patients with kidney failure requiring chronic dialysis, we performed a post-hoc analysis of the randomized German Diabetes Dialysis (4D) Study; this study included 1255 European patients on hemodialysis with diabetes followed-up for a median of 4 years. The results obtained via Cox proportional hazards models were confirmed by competing risk regression and restricted cubic spline modeling in the 4D Study cohort and validated in a separate cohort of 104 US patients on dialysis after a median follow-up of 2.5 years. Results A total of 1108 patients had baseline oxalate measurements, with a median oxalate concentration of 42.4 µM. During follow-up, 548 patients died, including 139 (25.4%) from sudden cardiac death. A total of 413 patients reached the primary composite cardiovascular end point (cardiac death, nonfatal myocardial infarction, and fatal or nonfatal stroke). Patients in the highest oxalate quartile (≥59.7 µM) had a 40% increased risk for cardiovascular events (adjusted hazard ratio [aHR], 1.40; 95% confidence interval [95% CI], 1.08 to 1.81) and a 62% increased risk of sudden cardiac death (aHR, 1.62; 95% CI, 1.03 to 2.56), compared with those in the lowest quartile (≤29.6 µM). The associations remained when accounting for competing risks and with oxalate as a continuous variable. Conclusions Elevated serum oxalate is a novel risk factor for cardiovascular events and sudden cardiac death in patients on dialysis. Further studies are warranted to test whether oxalate-lowering strategies improve cardiovascular mortality in patients on dialysis.